{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:46Z","timestamp":1792598686450,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K15513"],"award-info":[{"award-number":["23K15513"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21K08749"],"award-info":[{"award-number":["21K08749"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["22H02912"],"award-info":[{"award-number":["22H02912"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["22K08766"],"award-info":[{"award-number":["22K08766"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["22K16480"],"award-info":[{"award-number":["22K16480"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K19496"],"award-info":[{"award-number":["23K19496"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1245\/s10434-024-16195-8","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T17:01:52Z","timestamp":1727542912000},"page":"1913-1924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Tumoral \u03b22-Adrenergic Receptor Expression on Chemotherapeutic Response and Prognosis in Patients with Advanced Colorectal Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Chika","family":"Komine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Yokobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuma","family":"Shioi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Osone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhisa","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroomi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"16195_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"16195_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the \u03b22 adrenergic receptor-Gs protein complex. Nature. 2011;477:549\u201355.","journal-title":"Nature"},{"key":"16195_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","volume":"23","author":"J Tang","year":"2013","unstructured":"Tang J, Li Z, Lu L, Cho CH. \u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23:533\u201342.","journal-title":"Semin Cancer Biol"},{"key":"16195_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18:1201\u20136.","journal-title":"Clin Cancer Res"},{"key":"16195_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10147-020-01645-6","volume":"25","author":"H Ogawa","year":"2020","unstructured":"Ogawa H, Kaira K, Motegi Y, et al. Prognostic significance of beta2-adrenergic receptor expression in patients with surgically resected colorectal cancer. Int J Clin Oncol. 2020;25:1137\u201344.","journal-title":"Int J Clin Oncol"},{"key":"16195_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.21873\/anticanres.13125","volume":"39","author":"K Kaira","year":"2019","unstructured":"Kaira K, Kamiyoshihara M, Kawashima O, et al. Prognostic impact of beta2 adrenergic receptor expression in surgically resected pulmonary pleomorphic carcinoma. Anticancer Res. 2019;39:395\u2013403.","journal-title":"Anticancer Res"},{"key":"16195_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-019-05341-6","volume":"177","author":"S Kurozumi","year":"2019","unstructured":"Kurozumi S, Kaira K, Matsumoto H, et al. beta2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2019;177:603\u201310.","journal-title":"Breast Cancer Res Treat"},{"key":"16195_CR8","doi-asserted-by":"publisher","first-page":"13885","DOI":"10.1007\/s13277-016-5139-2","volume":"37","author":"K Takahashi","year":"2016","unstructured":"Takahashi K, Kaira K, Shimizu A, et al. Clinical significance of \u03b22-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. Tumour Biol. 2016;37:13885\u201392.","journal-title":"Tumour Biol"},{"key":"16195_CR9","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1245\/s10434-012-2396-1","volume":"19","author":"D Chen","year":"2012","unstructured":"Chen D, Xing W, Hong J, et al. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19:3556\u201365.","journal-title":"Ann Surg Oncol"},{"key":"16195_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41419-019-2030-2","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhang Y, He Z, et al. Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis. 2019;10:788.","journal-title":"Cell Death Dis"},{"key":"16195_CR11","first-page":"5059","volume":"8","author":"T Yazawa","year":"2016","unstructured":"Yazawa T, Kaira K, Shimizu K, et al. Prognostic significance of \u03b22-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res. 2016;8:5059\u201370.","journal-title":"Am J Transl Res"},{"key":"16195_CR12","doi-asserted-by":"publisher","first-page":"e61435","DOI":"10.1371\/journal.pone.0061435","volume":"8","author":"Q Lin","year":"2013","unstructured":"Lin Q, Wang F, Yang R, Zheng X, Gao H, Zhang P. Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One. 2013;8:e61435.","journal-title":"PLoS One"},{"key":"16195_CR13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.3892\/or.2015.3874","volume":"33","author":"M Coelho","year":"2015","unstructured":"Coelho M, Moz M, Correia G, Teixeira A, Medeiros R, Ribeiro L. Antiproliferative effects of beta-blockers on human colorectal cancer cells. Oncol Rep. 2015;33:2513\u201320.","journal-title":"Oncol Rep"},{"key":"16195_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11481-019-09891-w","volume":"15","author":"MB Nilsson","year":"2020","unstructured":"Nilsson MB, Le X, Heymach JV. \u03b2-Adrenergic signaling in lung cancer: a potential role for beta-blockers. J Neuroimmune Pharmacol. 2020;15:27\u201336.","journal-title":"J Neuroimmune Pharmacol"},{"key":"16195_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41420-022-00818-8","volume":"8","author":"Y Xu","year":"2022","unstructured":"Xu Y, Wang J, Wang X, et al. Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors. Cell Death Discov. 2022;8:36.","journal-title":"Cell Death Discov"},{"key":"16195_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/onc.2015.58","volume":"35","author":"D Liu","year":"2016","unstructured":"Liu D, Yang Z, Wang T, et al. beta2-AR signaling controls trastuzumab resistance-dependent pathway. Oncogene. 2016;35:47\u201358.","journal-title":"Oncogene"},{"key":"16195_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psyneuen.2014.11.008","volume":"52","author":"J Liu","year":"2015","unstructured":"Liu J, Deng GH, Zhang J, et al. The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models. Psychoneuroendocrinology. 2015;52:130\u201342.","journal-title":"Psychoneuroendocrinology"},{"key":"16195_CR18","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.4049\/jimmunol.1202364","volume":"190","author":"M Shi","year":"2013","unstructured":"Shi M, Yang Z, Hu M, et al. Catecholamine-induced \u03b22-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol. 2013;190:5600\u20138.","journal-title":"J Immunol"},{"key":"16195_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jhep.2016.04.019","volume":"65","author":"FQ Wu","year":"2016","unstructured":"Wu FQ, Fang T, Yu LX, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1\u03b1. J Hepatol. 2016;65:314\u201324.","journal-title":"J Hepatol"},{"key":"16195_CR20","doi-asserted-by":"publisher","first-page":"eaao4307","DOI":"10.1126\/scitranslmed.aao4307","volume":"9","author":"MB Nilsson","year":"2017","unstructured":"Nilsson MB, Sun H, Diao L, et al. Stress hormones promote EGFR inhibitor resistance in NSCLC: implications for combinations with \u03b2-blockers. Sci Transl Med. 2017;9:eaao4307.","journal-title":"Sci Transl Med"},{"key":"16195_CR21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/cas.13275","volume":"108","author":"H Chen","year":"2017","unstructured":"Chen H, Zhang W, Cheng X, et al. beta2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells. Cancer Sci. 2017;108:1310\u20137.","journal-title":"Cancer Sci"},{"key":"16195_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1158\/1078-0432.CCR-15-1275","volume":"22","author":"Y Kang","year":"2016","unstructured":"Kang Y, Nagaraja AS, Armaiz-Pena GN, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clin Cancer Res. 2016;22:1713\u201324.","journal-title":"Clin Cancer Res"},{"key":"16195_CR23","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1158\/0008-5472.CAN-17-0546","volume":"77","author":"MJ Bucsek","year":"2017","unstructured":"Bucsek MJ, Qiao G, MacDonald CR, et al. \u03b2-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res. 2017;77:5639\u201351.","journal-title":"Cancer Res"},{"key":"16195_CR24","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers11121856","volume":"11","author":"O Fiala","year":"2019","unstructured":"Fiala O, Ostasov P, Sorejs O, et al. Incidental use of beta-blockers is associated with outcome of metastatic colorectal cancer patients treated with bevacizumab-based therapy: a single-institution retrospective analysis of 514 patients. Cancers (Basel). 2019;11:1856.","journal-title":"Cancers (Basel)"},{"key":"16195_CR25","doi-asserted-by":"publisher","first-page":"175718","DOI":"10.1016\/j.ejphar.2023.175718","volume":"949","author":"Y Lin","year":"2023","unstructured":"Lin Y, Liu Y, Gao Z, et al. Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer. Eur J Pharmacol. 2023;949:175718.","journal-title":"Eur J Pharmacol"},{"key":"16195_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.18632\/oncotarget.343","volume":"2","author":"E Pasquier","year":"2011","unstructured":"Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2:797\u2013809.","journal-title":"Oncotarget"},{"key":"16195_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10549-021-06210-x","volume":"188","author":"MB Hopson","year":"2021","unstructured":"Hopson MB, Lee S, Accordino M, et al. Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. Breast Cancer Res Treat. 2021;188:427\u201332.","journal-title":"Breast Cancer Res Treat"},{"key":"16195_CR28","doi-asserted-by":"publisher","first-page":"10465","DOI":"10.1038\/s41598-020-67342-6","volume":"10","author":"L Porcelli","year":"2020","unstructured":"Porcelli L, Garofoli M, Di Fonte R, et al. The \u03b2-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Sci Rep. 2020;10:10465.","journal-title":"Sci Rep"},{"key":"16195_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-20-2381","volume":"27","author":"S Gandhi","year":"2021","unstructured":"Gandhi S, Pandey MR, Attwood K, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 2021;27:87\u201395.","journal-title":"Clin Cancer Res"},{"key":"16195_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2011.04.055","volume":"665","author":"T Shan","year":"2011","unstructured":"Shan T, Ma Q, Zhang D, et al. beta2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol. 2011;665:1\u20137.","journal-title":"Eur J Pharmacol"},{"key":"16195_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2023.03.046","volume":"657","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen F, Sun X, et al. Sympathetic \u03b2(2)-adrenergic receptor blockade overcomes docetaxel resistance in prostate cancer. Biochem Biophys Res Commun. 2023;657:69\u201379.","journal-title":"Biochem Biophys Res Commun"},{"key":"16195_CR32","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","volume":"41","author":"KY Fj\u00e6stad","year":"2022","unstructured":"Fj\u00e6stad KY, R\u00f8mer AMA, Goitea V, et al. Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene. 2022;41:1364\u201375.","journal-title":"Oncogene"},{"key":"16195_CR33","doi-asserted-by":"publisher","first-page":"614288","DOI":"10.3389\/fonc.2020.614288","volume":"10","author":"J Saha","year":"2020","unstructured":"Saha J, Kim JH, Amaya CN, et al. Propranolol sensitizes vascular sarcoma cells to doxorubicin by altering lysosomal drug sequestration and drug efflux. Front Oncol. 2020;10:614288.","journal-title":"Front Oncol"},{"key":"16195_CR34","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","volume":"140","author":"CH Choi","year":"2014","unstructured":"Choi CH, Song T, Kim TH, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014;140:1179\u201388.","journal-title":"J Cancer Res Clin Oncol"},{"key":"16195_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","volume":"25","author":"S Zhong","year":"2016","unstructured":"Zhong S, Yu D, Zhang X, et al. \u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prev. 2016;25:440\u20138.","journal-title":"Eur J Cancer Prev"},{"key":"16195_CR36","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084\u201391.","journal-title":"J Clin Oncol"},{"key":"16195_CR37","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006\u201312.","journal-title":"J Clin Oncol"},{"key":"16195_CR38","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.bjc.6604271","volume":"98","author":"Y Yamada","year":"2008","unstructured":"Yamada Y, Tahara M, Miya T, et al. Phase I\/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 2008;98:1034\u20138.","journal-title":"Br J Cancer"},{"key":"16195_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clcc.2013.12.004","volume":"13","author":"Y Guo","year":"2014","unstructured":"Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J. Capecitabine plus irinotecan versus 5-FU\/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. Clin Colorectal Cancer. 2014;13:110\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"16195_CR40","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/annonc\/mdl066","volume":"17","author":"A Goto","year":"2006","unstructured":"Goto A, Yamada Y, Yasui H, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 2006;17:968\u201373.","journal-title":"Ann Oncol"},{"key":"16195_CR41","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041\u20137.","journal-title":"Lancet"},{"key":"16195_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"16195_CR43","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.1097\/MD.0000000000000719","volume":"94","author":"R Giampieri","year":"2015","unstructured":"Giampieri R, Scartozzi M, Del Prete M, et al. Prognostic value for incidental antihypertensive therapy with beta-blockers in metastatic colorectal cancer. Medicine (Baltimore). 2015;94:e719.","journal-title":"Medicine (Baltimore)"},{"key":"16195_CR44","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.3747\/co.25.4069","volume":"25","author":"S Sud","year":"2018","unstructured":"Sud S, O\u2019Callaghan C, Jonker C, et al. Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. Curr Oncol. 2018;25:e516\u201326.","journal-title":"Curr Oncol"},{"key":"16195_CR45","doi-asserted-by":"publisher","first-page":"17891","DOI":"10.1002\/cam4.6424","volume":"12","author":"C Schuster","year":"2023","unstructured":"Schuster C, Akslen LA, Straume O. \u03b22-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma. Cancer Med. 2023;12:17891\u2013900.","journal-title":"Cancer Med"},{"key":"16195_CR46","doi-asserted-by":"publisher","first-page":"735278","DOI":"10.3389\/fphar.2021.735278","volume":"12","author":"J Hu","year":"2021","unstructured":"Hu J, Chen C, Lu R, et al. \u03b2-Adrenergic receptor inhibitor and oncolytic herpesvirus combination therapy shows enhanced antitumoral and antiangiogenic effects on colorectal cancer. Front Pharmacol. 2021;12:735278.","journal-title":"Front Pharmacol"},{"key":"16195_CR47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/labinvest.2012.175","volume":"93","author":"S Moretti","year":"2013","unstructured":"Moretti S, Massi D, Farini V, et al. \u03b2-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Investig. 2013;93:279\u201390.","journal-title":"Lab Investig"},{"key":"16195_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm1447","volume":"12","author":"PH Thaker","year":"2006","unstructured":"Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939\u201344.","journal-title":"Nat Med"},{"key":"16195_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbi.2008.10.005","volume":"23","author":"EV Yang","year":"2009","unstructured":"Yang EV, Kim S, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behavior Immun. 2009;23:267\u201375.","journal-title":"Brain Behavior Immun"},{"issue":"12","key":"16195_CR50","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1172\/JCI129502","volume":"129","author":"H Mohammadpour","year":"2019","unstructured":"Mohammadpour H, MacDonald CR, Qiao G, et al. \u03b22 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J Clin Investig. 2019;129(12):5537\u201352.","journal-title":"J Clin Investig"},{"issue":"4","key":"16195_CR51","doi-asserted-by":"publisher","first-page":"109883","DOI":"10.1016\/j.celrep.2021.109883","volume":"37","author":"H Mohammadpour","year":"2021","unstructured":"Mohammadpour H, MacDonald CR, McCarthy PL, Abrams SI, Repasky EA. \u03b22-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. Cell Rep. 2021;37(4):109883.","journal-title":"Cell Rep"},{"issue":"16","key":"16195_CR52","doi-asserted-by":"publisher","first-page":"e93076","DOI":"10.1172\/jci.insight.93076","volume":"2","author":"AS Nagaraja","year":"2017","unstructured":"Nagaraja AS, Dood RL, Armaiz-Pena G, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017;2(16):e93076.","journal-title":"JCI Insight"},{"issue":"4","key":"16195_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41577-023-00949-8","volume":"24","author":"Y Ma","year":"2024","unstructured":"Ma Y, Kroemer G. The cancer-immune dialogue in the context of stress. Nat Rev Immunol. 2024;24(4):264\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"16195_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12929-023-00903-9","volume":"30","author":"J Yan","year":"2023","unstructured":"Yan J, Chen Y, Luo M, et al. Chronic stress in solid tumor development: from mechanisms to interventions. J Biomed Sci. 2023;30(1):8.","journal-title":"J Biomed Sci"},{"issue":"1","key":"16195_CR55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2326-6066.CIR-17-0401","volume":"6","author":"MD Nissen","year":"2018","unstructured":"Nissen MD, Sloan EK, Mattarollo SR. \u03b2-Adrenergic signaling impairs antitumor CD8(+) T-cell responses to B-cell lymphoma immunotherapy. Cancer Immunol Res. 2018;6(1):98\u2013109.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"16195_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5483\/BMBRep.2015.48.5.008","volume":"48","author":"JF Qin","year":"2015","unstructured":"Qin JF, Jin FJ, Li N, et al. Adrenergic receptor \u03b22 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep. 2015;48(5):295\u2013300.","journal-title":"BMB Rep"},{"key":"16195_CR57","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.12669\/pjms.38.5.5311","volume":"38","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chen Y, Wang Z, Li H, Wang Y. Clinical value of propranolol combined with oxaliplatin and tigio in concurrent chemoradiotherapy for locally advanced gastric cancer. Pak J Med Sci. 2022;38:1316\u201320.","journal-title":"Pak J Med Sci"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16195-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16195-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16195-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T14:01:48Z","timestamp":1739196108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16195-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["16195"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16195-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}